uploads///Analysts Ratings

Analysts’ Recommendations for Pfizer in August 2017

By

Dec. 4 2020, Updated 10:53 a.m. ET

Recent approval

In August 2017, the FDA approved Pfizer’s Besponsa therapy for adult individuals with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (or ALL). The FDA’s approval of Besponsa was based on the Phase 3 INO-VATE ALL trial.

In the Phase 3 INO-VATE trial, 81% of the patients receiving Besponsa achieved a complete remission rate (or CR) compared to 29% of the patients on chemotherapy. Further, patients receiving Besponsa demonstrated a higher rate of minimal residual disease (or MRD) negativity (~78% of patients) compared to patients receiving chemotherapy (~28% of patients). Patients treated with Beponsa had median overall survival (or OS) of 7.7 months compared to 6.2 months for patients receiving chemotherapy.

Article continues below advertisement

Analysts’ recommendations

Of the 22 analysts covering Pfizer (PFE) in August 2017, one analyst recommended a “strong buy” and ten analysts recommended a “buy.” Ten analysts suggested a “hold,” none of the analysts recommended a “sell,” and one analyst suggested a “strong sell.”

Around 50% of the analysts tracking Pfizer in August 2017 suggested some form of a “buy” rating. On August 26, 2017, Pfizer had a consensus 12-month target price of $37.45, which represents a 12.7% return on investment. The Vanguard High Dividend Yield ETF (VYM) invests ~2.1% of its total portfolio holdings in Pfizer. VYM also invests ~3.9% of its total portfolio holdings in Johnson & Johnson (JNJ).

Peer ratings

Of the 20 analysts tracking Alexion Pharmaceuticals (ALXN) in August 2017, six analysts recommended a “strong buy,” ten analysts recommended a “buy,” and four analysts recommended a “hold.” None of the analysts recommended a “sell” or a “strong sell.”

Around 80% of the analysts tracking Alexion Pharmaceuticals in August 2017 suggested some form of a “buy” rating. On August 26, 2017, Alexion Pharmaceuticals had a consensus 12-month target price of $158.95, which represents an ~15.4% return on investment.

Of the 20 analysts covering Abbott Laboratories (ABT) in August 2017, seven analysts recommended a “strong buy,” six analysts recommended a “buy,” and seven analysts recommended a “hold.” None of the analysts recommended a “sell” or “strong sell.”

Around 65% of the analysts tracking Abbott Laboratories in August 2017 suggested some form of a “buy” rating. On August 26, 2017, Abbott Laboratories had a consensus 12-month target price of $54.94, which represents an ~11.3% return on investment.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.